Dear Editor,
We read with great interest the recent study by Li et al, 1 which investigates the potential survival benefit of adding moxibustion (Moxa) treatment to conventional Western and Chinese herbal therapies in patients with stage-IV pulmonary adenocarcinoma (PUAD-IV). The authors reported a significant, dose-dependent improvement in median survival time (MST) associated with moxibustion treatment. Given the limited therapeutic options and prognosis for patients with advanced adenocarcinoma, this study provides valuable evidence that supports the integrative use of traditional Chinese medicine (TCM) alongside conventional therapies. Despite the important clinical implications, several methodological issues need further clarification to better interpret the reported findings.
First, the authors applied propensity score analysis (PSA) to adjust for baseline covariate imbalances between groups receiving different moxibustion dosages. However, the classification of moxibustion exposure as “none,” “1-4 times,” and “>4 times” remains broad and potentially imprecise. The study did not specify exact intervals or frequencies clearly for each dosage group. Given that therapeutic efficacy and physiological responses to moxibustion may vary substantially with even small changes in dosage frequency or timing, 2 providing more precise data on treatment intervals could significantly enhance clinical applicability and reproducibility of findings. A previous meta-analysis has indicated that the therapeutic effectiveness of acupuncture and related TCM modalities is closely related to precise dosing regimens. 3
Second, while the study adjusted for baseline covariates through PSA, it remains unclear whether and how the changes in patients’ conditions during follow-up were addressed analytically. Given that patients received Moxa treatments based on evolving TCM syndromes, it is plausible that those receiving more treatments were inherently different, potentially biasing survival outcomes. Thus, incorporating a time-dependent analysis might have provided more robust insights into the effectiveness of Moxa treatments relative to patient status changes over the follow-up period.
Lastly, although the authors reported promising survival improvements, the precise biological mechanisms underpinning the beneficial effects of moxibustion in PUAD-IV remain speculative. While previous research highlighted potential immunological mechanisms, including modulation of natural killer cells and inflammatory cytokines,4,5 it would have been informative for the authors to discuss how their findings could translate into actionable clinical practice or guide mechanistic studies more clearly.
In summary, Li et al’s work provides encouraging evidence supporting moxibustion as an adjunctive treatment in advanced pulmonary adenocarcinoma. However, addressing these methodological concerns, particularly regarding dosage precision, time-dependent treatment assignment, and mechanistic clarification, will substantially enhance the reliability, validity, and translational value of their findings. We look forward to future randomized controlled trials designed to rigorously test these hypotheses.
Xingjian Wang, MD
Department of Respiratory Medicine, Chongqing General Hospital of the Chinese People’s Armed Police Force, China
Keyuan Liu, MD
Department of Respiratory Medicine, Chongqing General Hospital of the Chinese People’s Armed Police Force, China
Jie Zhao, MD
Department of Respiratory Medicine, Chongqing General Hospital of the Chinese People’s Armed Police Force, China
Xinglong Li, MD
Ping Gan, MD
Department of Respiratory Medicine, Chongqing General Hospital of the Chinese People’s Armed Police Force, China
Footnotes
ORCID iD: Ping Gan 
https://orcid.org/0009-0000-6509-4835
Author Contributions: XJ.W. and KY. L.: Contributed to the conceptualization of the letter, writing the manuscript. J.Z. and XL.L.: Critical revision of intellectual content. P.G.: Provided supervision, contributed to the refinement of ideas, ensured the accuracy of the content, and approved the final version of the manuscript. XJ.W. and KY. L contributed equally to this work.
Data Availability Statement: No datasets were generated or analyzed during the current study.
References
- 1. Li H, Lindberg V, Zhu L, Huang X, Feng J, Baak JPA. Moxibustion treatment, alongside conventional Western and Chinese herbal medical therapies, may improve survival in stage-IV pulmonary adenocarcinomas in a dosage-dependent manner: a prospective observational study with propensity score analysis. Integr Cancer Ther. 2025;24:15347354251342739. doi: 10.1177/15347354251342739 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Bauer M, McDonald JL, Saunders N. Is acupuncture dose dependent? Ramifications of acupuncture treatment dose within clinical practice and trials. Integr Med Res. 2020;9(1):21-27. doi: 10.1016/j.imr.2020.01.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Sun N, Tu JF, Lin LL, et al. Correlation between acupuncture dose and effectiveness in the treatment of knee osteoarthritis: a systematic review. Acupunct Med. 2019;37(5):261-267. doi: 10.1136/acupmed-2017-011608 [DOI] [PubMed] [Google Scholar]
- 4. Hu D, Shen W, Gong C, et al. Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer. J Cell Mol Med. 2021;25(6):2900-2908. doi: 10.1111/jcmm.16320 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Zhao Z, Li J, Wen J, He Y, Sun Z. Effect of moxibustion on inflammatory cytokines for low back pain: a systematic review, meta-analysis and meta-regression. Ther Clin Risk Manag. 2023;19:811-827. doi: 10.2147/TCRM.S429469 [DOI] [PMC free article] [PubMed] [Google Scholar]